Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Ther
(NQ:
ITCI
)
69.56
+0.49 (+0.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intra-Cellular Ther
< Previous
1
2
3
4
5
Next >
Analyst Ratings for Intra-Cellular Therapies
July 07, 2022
Over the past 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
June 09, 2022
According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of...
Via
Benzinga
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
May 11, 2022
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.
Via
Investor's Business Daily
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
May 10, 2022
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
Gainers
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 10, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
April 22, 2022
Upgrades
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intra-Cellular Therapies
April 21, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:
Via
Benzinga
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
Intra-Cellular Therapies's Return On Capital Employed Insights
March 04, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $25.67 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 11.48%, resulting...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Intra-Cellular Therapies
March 02, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Intra-Cellular Therapies: Q4 Earnings Insights
March 01, 2022
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Where Intra-Cellular Therapies Stands With Analysts
February 16, 2022
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Expert Ratings For Intra-Cellular Therapies
February 16, 2022
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Intra-Cellular Therapies Inc.: The Winning Streak Continues
February 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Intra-Cellular Therapies Inc. (NASDAQ:...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2022
February 16, 2022
Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49...
Via
Benzinga
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 21, 2022
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...
Via
Benzinga
53 Biggest Movers From Friday
January 24, 2022
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...
Via
Benzinga
34 Stocks Moving In Friday's Mid-Day Session
January 21, 2022
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....
Via
Benzinga
45 Biggest Movers From Yesterday
January 05, 2022
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 04, 2022
Gainers Hoth Therapeutics (NASDAQ:
Via
Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
January 04, 2022
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 04, 2022
Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 68.7% to $1.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $28....
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.